Nowak Przemysław, Dabrowska Joanna, Bortel Aleksandra, Biedka Izabela, Szczerbak Grazyna, Słomian Grzegorz, Kostrzewa Richard M, Brus Ryszard
Department of Pharmacology, Medical University of Silesia, H. Jordana 38, 41-808 Zabrze, Poland.
Eur J Pharmacol. 2006 Dec 15;552(1-3):46-54. doi: 10.1016/j.ejphar.2006.08.092. Epub 2006 Sep 16.
In rats lesioned neonatally with 6-hydroxydopamine (6-OHDA), repeated treatment with SKF 38393 (1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol), a dopamine D(1)/D(5) receptor agonist, produces robust stereotyped and locomotor activities. The gradual induction of dopamine D(1) receptor supersensitivity is known as a priming phenomenon, and this process is thought to underlie not only the appearance of vacuous chewing movements in humans with tardive dyskinesia, but also the onset of motor dyskinesias in L-dihydroxyphenylalanine (L-DOPA)-treated Parkinson's disease patients. The object of the present study was to determine the possible influence of the histaminergic system on dopamine D(1) agonist-induced activities. We found that neither imetit (5.0 mg/kg i.p.), a histamine H(3) receptor agonist, nor thioperamide (5.0 mg/kg i.p.), a histamine H(3) receptor antagonist/inverse agonist, altered the numbers of vacuous chewing movements in non-primed-lesioned rats. However, in dopamine D(1) agonist-primed rats, thioperamide alone produced a vacuous chewing movements response (i.e., P < 0.05 vs SKF 38393, 1.0 mg/kg i.p.), but did not modify the SKF 38393 effect. Notably, both imetit and thioperamide-induced catalepsy in both non-primed and primed 6-OHDA-lesioned rats, comparable in magnitude to the effect of the dopamine D(1)/D(5) receptor antagonist SCH 23390 (7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 0.5 mg/kg i.p.). Furthermore, in primed animals both imetit and thioperamide intensified SCH 23390-evoked catalepsy. In vivo microdialysis established that neither imetit nor thioperamide altered extraneuronal levels of dopamine and its metabolites in the striatum of 6-OHDA-lesioned rats. On the basis of the present study, we believe that histaminergic systems may augment dyskinesias induced by dopamine receptor agonists, independent of direct actions on dopaminergic neurons.
在新生期用6-羟基多巴胺(6-OHDA)损伤的大鼠中,重复给予SKF 38393(1-苯基-2,3,4,5-四氢-(1H)-3-苯并氮杂卓-7,8-二醇),一种多巴胺D(1)/D(5)受体激动剂,会产生强烈的刻板运动和自发运动。多巴胺D(1)受体超敏反应的逐渐诱导被称为启动现象,并且这个过程被认为不仅是迟发性运动障碍患者出现无意义咀嚼运动的基础,也是左旋多巴(L-DOPA)治疗的帕金森病患者运动障碍发作的基础。本研究的目的是确定组胺能系统对多巴胺D(1)激动剂诱导的活动可能产生的影响。我们发现,组胺H(3)受体激动剂艾美替丁(5.0 mg/kg腹腔注射)和组胺H(3)受体拮抗剂/反向激动剂硫代哌酰胺(5.0 mg/kg腹腔注射)都不会改变未启动损伤大鼠的无意义咀嚼运动次数。然而,在多巴胺D(1)激动剂启动的大鼠中,单独使用硫代哌酰胺会产生无意义咀嚼运动反应(即,与腹腔注射1.0 mg/kg的SKF 38393相比,P < 0.05),但不会改变SKF 38393的作用。值得注意的是,艾美替丁和硫代哌酰胺在未启动和启动的6-OHDA损伤大鼠中均诱导了僵住症,其程度与多巴胺D(1)/D(5)受体拮抗剂SCH 23390(7-氯-8-羟基-3-甲基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓;0.5 mg/kg腹腔注射)的作用相当。此外,在启动的动物中,艾美替丁和硫代哌酰胺都会增强SCH 23390诱发的僵住症。体内微透析表明,艾美替丁和硫代哌酰胺都不会改变6-OHDA损伤大鼠纹状体中多巴胺及其代谢物的细胞外水平。基于本研究,我们认为组胺能系统可能会增强多巴胺受体激动剂诱导的运动障碍,这与对多巴胺能神经元的直接作用无关。